CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Immunitybio Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Immunitybio Inc
3530 JOHN HOPKINS COURT
Phone: (858) 633-0300p:858 633-0300 SAN DIEGO, CA  92121  United States Ticker: IBRXIBRX

Business Summary
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202312/31/2023YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Executive Chairman of the Board, Global Chief Scientific and Medical Officer PatrickSoon-Shiong 70 8/11/2021 3/1/2015
President, Chief Executive Officer, Director RichardAdcock 54 3/29/2021 10/26/2020
Chief Financial Officer DavidSachs 45 3/5/2021 3/5/2021
8 additional Officers and Directors records available in full report.

Business Names
Business Name
557 Doug St, LLC
AccessBio LLC
Altor BioScience Manufacturing Company, LLC
18 additional Business Names available in full report.

General Information
Number of Employees: 628 (As of 12/31/2023)
Outstanding Shares: 673,952,278 (As of 3/14/2024)
Shareholders: 91
Stock Exchange: NASD
Federal Tax Id: 431979754
Fax Number: (302) 674-5266


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024